Artiva Biotherapeutics, Inc.
ARTV
$5.52
-$0.28-4.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 0.00 | 251.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 251.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 0.00 | 251.00K |
| SG&A Expenses | 20.27M | 20.28M | 19.83M | 18.74M | 17.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.81M | 86.15M | 81.58M | 74.96M | 67.54M |
| Operating Income | -89.81M | -86.15M | -81.58M | -74.96M | -67.28M |
| Income Before Tax | -83.87M | -79.19M | -75.13M | -71.72M | -65.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.87 | -79.19 | -75.13 | -71.72 | -65.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.87M | -79.19M | -75.13M | -71.72M | -65.37M |
| EBIT | -89.81M | -86.15M | -81.58M | -74.96M | -67.28M |
| EBITDA | -87.21M | -83.60M | -79.07M | -72.49M | -64.85M |
| EPS Basic | -3.43 | -3.25 | -3.29 | -24.41 | -40.82 |
| Normalized Basic EPS | -2.19 | -2.09 | -2.12 | -15.32 | -25.57 |
| EPS Diluted | -3.43 | -3.25 | -3.29 | -24.41 | -40.82 |
| Normalized Diluted EPS | -2.19 | -2.09 | -2.12 | -15.32 | -25.57 |
| Average Basic Shares Outstanding | 97.77M | 97.59M | 92.00M | 68.44M | 44.90M |
| Average Diluted Shares Outstanding | 97.77M | 97.59M | 92.00M | 68.44M | 44.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |